| Literature DB >> 32961973 |
Athanasia Tragomalou1,2, George Moschonis3, Penio Kassari1,2, Ifigeneia Papageorgiou1, Sofia-Maria Genitsaridi1, Sofia Karampatsou1, Yannis Manios4, Evangelia Charmandari1,2.
Abstract
Obesity in childhood and adolescence represents one of the most challenging public health problems of the 21st century owing to its epidemic proportions worldwide and the associated significant morbidity, mortality and public health costs. In Greece, the prevalence of overweight and obesity in childhood and adolescence exceeds 30-35%. To address the increasing prevalence of overweight and obesity in children and adolescents in our country, we developed the 'National e-Health Program for the Prevention and Management of Overweight and Obesity in Childhood and Adolescence', which provides specific and detailed guidance to all primary health care physicians about the personalized management of children and adolescents with overweight or obesity. In the present study we evaluated 2400 children and adolescents [mean age ± SEM: 10.10 ± 0.09 years.; Males: 1088, Females: 1312; Obesity (n = 1370, 57.1%), Overweight (n = 674, 28.1%), normal BMI (n = 356, 14.8%)], who followed the personalized multi-disciplinary management plan specified by the 'National e-Health Program for the Prevention and Management of Overweight and Obesity in Childhood and Adolescence', and were studied prospectively for 1 year. We demonstrated that at the end of the first year, the prevalence of obesity decreased by 32.1%, the prevalence of overweight decreased by 26.7%, and the cardiometabolic risk factors improved significantly. These findings indicate that our National e-Health Program is effective at reducing the prevalence of overweight and obesity in childhood and adolescence after one year of intervention in the largest sample size reported to date.Entities:
Keywords: cardiometabolic risk factors; national e-health program; overweight and obesity in childhood and adolescence
Mesh:
Year: 2020 PMID: 32961973 PMCID: PMC7551883 DOI: 10.3390/nu12092858
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Clinical characteristics of all subjects at initial assessment.
| Obesity | Overweight | Normal-BMI | ||
|---|---|---|---|---|
|
| 10.10 ± 0.09 | 10.20 ± 0.11 | 9.80 ± 0.16 | 0.147 |
|
| 62.78 ± 0.65 | 49.41 ± 0.54 | 38.79 ± 0.73 |
|
|
| 144.47 ± 0.52 | 143.43 ± 0.58 | 139.03 ± 0.94 |
|
|
| 28.70 ± 0.14 | 23.40 ± 0.09 | 19.31 ± 0.16 |
|
|
| 0.95 ± 0.01 | 0.93 ± 0.01 | 0.88 ± 0.01 |
|
|
| 0.61 ± 0.003 | 0.55 ± 0.003 | 0.51 ± 0.005 |
|
|
| 114 ± 0.39 | 110 ± 0.45 | 105 ± 0.62 |
|
|
| 67 ± 0.32 | 66 ± 0.75 | 63 ± 0.50 |
|
|
| ||||
| Prepubertal | 732 (57.1) | 367 (28.6) | 183 (14.3) | 0.829 |
| Pubertal | 599 (57) | 294 (27.9) | 159 (15.1) | |
|
| ||||
| Normal BMI | 300 (41.7) | 249 (34.6) | 170 (23.6) |
|
| Overweight | 331 (61) | 142 (26.2) | 70 (12.9) | |
| Obesity | 367 (69.4) | 109 (20.6) | 53 (10) | |
|
| ||||
| Normal BMI | 147 (41.2) | 124 (34.7) | 86 (24.1) |
|
| Overweight | 388 (53.2) | 228 (31.3) | 113 (15.5) | |
| Obesity | 455 (65.8) | 149 (21.5) | 88 (12.7) |
Abbreviations: DBP: Diastolic Blood Pressure, SBP: Systolic Blood Pressure; Continuous variables are presented as mean ± standard error of the mean (SEM) and categorical as frequencies (percentages); p values were derived by comparisons between the three categories of BMI using one-way ANOVA; Pearson’s χ2 for categorical variables; Statistically significant associations are shown in bold.
Figure 1Distribution of BMI: (A) in all subjects, (B) according to gender.
Clinical characteristics of all subjects after a year of intervention.
| Obesity | Overweight | Normal-BMI | ||
|---|---|---|---|---|
|
| 11.20 ± 0.16 | 10.96 ± 0.14 | 11.18 ± 0.20 | 0.345 |
|
| 68 ± 1.15 | 53.60 ± 0.77 | 45 ± 0.85 |
|
|
| 150.47 ± 0.87 | 149.11 ± 0.80 | 147 ± 1.04 |
|
|
| 28.87 ± 0.24 | 23.53 ± 0.12 | 20.37 ± 0.17 |
|
|
| 0.93 ± 0.005 | 0.91 ± 0.005 | 0.86 ± 0.007 |
|
|
| 0.60 ± 0.004 | 0.53 ± 0.003 | 0.49 ± 0.005 |
|
|
| 115 ± 0.79 | 111 ± 0.66 | 107 ± 0.85 |
|
|
| 69 ± 0.62 | 67 ± 0.59 | 65 ± 0.69 |
|
|
| ||||
| Prepubertal | 107 (42.3) | 103 (40.7) | 43 (17) |
|
| Pubertal | 165 (38.6) | 155 (36.2) | 108 (25.2) | |
|
| ||||
| Normal BMI | 88 (29.6) | 118 (39.7) | 91 (30.6) |
|
| Overweight | 95 (42.2) | 84 (37.3) | 46 (20.4) | |
| Obesity | 136 (53.8) | 89 (35.2) | 28 (11.1) | |
|
| ||||
| Normal BMI | 41 (27.3) | 59 (39.3) | 50 (33.3) |
|
| Overweight | 117 (37) | 126 (39.9) | 73 (23.1) | |
| Obesity | 157 (52.3) | 104 (34.7) | 39 (13) |
Abbreviations: DBP: Diastolic Blood Pressure, SBP: Systolic Blood Pressure WHratio: Waist to Hip ratio, WHtR: Waist to Height ratio; Continuous variables are presented as mean ± standard error of the mean (SEM) and categorical as frequencies (percentages); p values were derived by comparisons between the three categories of BMI using one-way ANOVA; Pearson’s χ2 for categorical variables; Statistically significant associations are shown in bold.
Biochemical and endocrinologic parameters in all subjects at baseline.
| Obesity | Overweight | Normal-BMI | ||
|---|---|---|---|---|
|
| 80.20 ± 0.28 | 78.72 ± 0.34 | 79.11 ± 0.43 |
|
|
| 157.11 ± 0.81 | 158.45 ± 1.17 | 159.71 ± 1.53 | 0.290 |
|
| 82.38 ± 1.28 | 73.99 ± 1.77 | 64.35 ± 1.79 |
|
|
| 50.05 ± 0.36 | 53.67 ± 0.53 | 59.51 ± 0.87 |
|
|
| 91.76 ± 0.72 | 90.96 ± 1.04 | 87.60 ± 1.32 |
|
|
| 138.86 ± 0.62 | 142.86 ± 0.89 | 149.76 ± 1.33 |
|
|
| 75.93 ± 0.53 | 73.69 ± 0.77 | 71.52 ± 0.88 |
|
|
| 17.46 ± 0.68 | 17.02 ± 0.97 | 17.98 ± 1.42 | 0.874 |
|
| 301.87 ± 5.10 | 306.64 ± 7.1 | 305.73 ± 10.66 | 0.517 |
|
| 5.09 ± 0.03 | 5.01 ± 0.04 | 4.82 ± 0.07 |
|
|
| 17.39 ± 0.32 | 12.50 ± 0.29 | 9.45 ± 0.34 |
|
|
| 5.26 ± 0.01 | 5.21 ± 0.01 | 5.18 ± 0.01 |
|
Abbreviations: ApoA1: Apolipoprotein A1, ApoB: Apolipoprotein B, HbA1c: Haemoglobin A1c, HDL: High-Density Lipoprotein, IGF-I: Insulin-like Growth Factor 1, IGF-BP3: IGF-binding protein 3, LDL: Low-Density Lipoprotein, Lp(a): Lipoprotein a, TG: Triglycerides, Continuous variables are presented as mean ± standard error of the mean (SEM); p values were derived by comparisons between the three categories of BMI using one-way ANOVA for normally distributed variables and Kruskal-Wallis H test for skewed variables; Statistically significant associations are shown in bold.
Lipid profile indicative of dyslipidemia at baseline.
| Obesity | Overweight | Normal-BMI | ||
|---|---|---|---|---|
|
| 213.98 ± 1.72 | 218.54 ± 3.15 | 218.63 ± 3.76 | 0.297 |
|
| 146.66 ± 2.34 | 146.47 ± 3.45 | 141.31 ± 4.26 | 0.598 |
|
| 124.69 ± 2.08 | 129.94 ± 4.87 | 117 ± 5.13 | 0.400 |
|
| ||||
|
| 133.95 ± 4.30 | 146.62 ± 8.87 | 123.29 ± 8.11 | 0.496 |
|
| 176.60 ± 5.73 | 180.55 ± 12.96 | 159.67 ± 14.82 | 0.152 |
|
| 35.04 ± 0.25 | 35.53 ± 0.43 | 34.23 ± 0.96 | 0.340 |
|
| 104.93 ± 0.88 | 107.49 ± 0.98 | 105.07 ± 2.24 | 0.241 |
|
| 57.23 ± 1.71 | 61.21 ± 2.74 | 61.97 ± 3.77 | 0.327 |
Abbreviations: ApoA1: Apolipoprotein A1, ApoB: Apolipoprotein B, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, Lp(a): Lipoprotein a.
Figure 2Alteration in BMI after 1 year of intervention: (A) in all subjects, (B) in boys, (C) in girls.
Biochemical and endocrinologic parameters in subjects with obesity.
| Initial Assessment | Annual Assessment | ||
|---|---|---|---|
|
| 80.11 ± 0.36 | 80.54 ± 0.10 | 0.269 |
|
| 158.57 ± 1.21 | 157.36 ± 1.38 | 0.056 |
|
| 82.36 ± 1.81 | 81.07 ± 1.84 | 0.657 |
|
| 50.23 ± 0.53 | 53.28 ± 0.60 |
|
|
| 92.39 ± 1.05 | 89.37 ± 1.14 |
|
|
| 140.55 ± 0.96 | 141.60 ± 1.03 | 0.163 |
|
| 75.59 ± 0.91 | 73.48 ± 0.78 |
|
|
| 16.45 ± 0.99 | 15.29 ± 1.05 |
|
|
| 20,705.41 ± 1203.62 | 23,115.45 ± 1239.64 |
|
|
| 17.52 ± 0.50 | 16.53 ± 0.42 | 0.321 |
|
| 5.28 ± 0.01 | 5.24 ± 0.01 |
|
Abbreviations: ApoA1: Apolipoprotein A1, ApoB: Apolipoprotein B, HbA1C: Hemoglobin A1C, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, Lp(a): Lipoprotein a.
Biochemical and endocrinologic parameters in subjects with overweight.
| Initial Assessment | Annual Assessment | ||
|---|---|---|---|
|
| 78.05 ± 0.51 | 80.55 ± 0.50 |
|
|
| 157.96 ± 1.76 | 156.91 ± 1.87 | 0.442 |
|
| 73.49 ± 2.64 | 74.63 ± 2.68 | 0.258 |
|
| 54.94 ± 3.16 | 55.79 ± 0.85 |
|
|
| 90.52 ± 1.55 | 87.50 ± 1.87 |
|
|
| 140.72 ± 1.40 | 143.15 ± 1.35 | 0.087 |
|
| 73.61 ± 1.23 | 71.19 ± 1.11 |
|
|
| 14.55 ± 1.26 | 14.18 ± 1.38 |
|
|
| 24,436.87 ± 1865.23 | 29,474.32 ± 2110.22 |
|
|
| 12.08 ± 0.40 | 13.14 ± 0.46 |
|
|
| 5.23 ± 0.01 | 5.21 ± 0.02 |
|
Abbreviations: ApoA1: Apolipoprotein A1, ApoB: Apolipoprotein B, HbA1C: Haemoglobin A1C, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, Lp(a): Lipoprotein a.
Biochemical and endocrinologic parameters in subjects with normal-BMI.
| Initial Assessment | Annual Assessment | ||
|---|---|---|---|
|
| 78.15 ± 0.73 | 79.06 ± 0.63 | 0.052 |
|
| 161.45 ± 2.66 | 158.11 ± 2.66 |
|
|
| 67.23 ± 3.15 | 69.27 ± 3.88 | 0.918 |
|
| 57.89 ± 1.32 | 60.68 ± 1.49 |
|
|
| 90.04 ± 2.26 | 83.76 ± 2.22 |
|
|
| 148.97 ± 2.02 | 147.79 ± 2.12 | 0.575 |
|
| 71.13 ± 1.42 | 69.43 ± 1.50 | 0.167 |
|
| 14.71 ± 1.89 | 15.90 ± 2.10 |
|
|
| 18,555.65 ± 2867.98 | 27,270.78 ± 3133.59 |
|
|
| 12.08 ± 0.40 | 13.14 ± 0.46 |
|
|
| 5.23 ± 0.01 | 5.21 ± 0.02 |
|
Abbreviations: ApoA1: Apolipoprotein A1, ApoB: Apolipoprotein B, HbA1C: Haemoglobin A1C, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, Lp(a): Lipoprotein a.
Figure 3Alteration of BMI after 1 year of intervention: (A) in obese children and adolescents, (B) in overweight children and adolescents, (C) in normal BMI children and adolescents.
Lipid profile alterations indicative of dyslipidemia following the multidisciplinary interventions.
| Initial Assessment | Annual Assessment | ||
|---|---|---|---|
|
| 221.23 ± 3.01 | 202.06 ± 4.22 |
|
|
| 142.33 ± 2 | 122.17 ± 3.02 |
|
|
| 130.16 ± 3.17 | 97.87 ± 4.61 |
|
|
| |||
|
| 130.60 ± 4.83 | 100.79 ± 5.70 |
|
|
| 174.68 ± 5.68 | 125.34 ± 7.77 |
|
|
| 35.39 ± 0.30 | 41.61 ± 0.74 |
|
|
| 95.36 ± 7.70 | 99.36 ± 1.59 | 0.629 |
|
| 58.77 ± 2.09 | 57.68 ± 2.90 | 0.113 |
Abbreviations: ApoA1: Apolipoprotein A1, ApoB: Apolipoprotein B, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, Lp(a): Lipoprotein a.